We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




People Identified at High-Risk of Developing Rheumatoid Arthritis

By LabMedica International staff writers
Posted on 14 Oct 2013
A new method identifies people at high-risk of developing rheumatoid arthritis, using a simple blood test and information about their smoking habits.

The new computer-based technique of prediction modeling allows researchers to combine both genetic and environmental risk factors to estimate an individual’s lifetime risk of developing this disease. More...
According to the study’s lead researcher, Dr. Ian Scott, department of genetics & molecular medicine at King’s College London, this new prediction modeling technique can also identify people at risk of developing rheumatoid arthritis at a younger age.

"This new computer-based technique of prediction modeling allows us to estimate someone’s risk of developing rheumatoid arthritis over their lifetime using genetic markers from a single blood test and information about their smoking habits," explained Dr. Scott.

"I hope that, as we understand the risk factors for rheumatoid arthritis better, our prediction modeling method could be used to screen people for this disease before they develop any symptoms. This is an important first step in trying to develop ways to prevent the onset of rheumatoid arthritis."

"Within the general population, few individuals that have clinically significant increased risks are likely to be identified using this approach. But targeted screening of people already at an increased risk of rheumatoid arthritis, such as relatives of patients, could identify enough high-risk people to allow researchers to look at ways to prevent rheumatoid arthritis from developing."

Individuals classed as being high risk, using information from the most important gene associated with rheumatoid arthritis (the HLA-DRB1 gene), are more likely to develop rheumatoid arthritis at a younger age. They could be monitored for early signs of the disease. Treating rheumatoid arthritis early, before significant joint damage has occurred, increases the likelihood that the individual will go into remission (no joint pain or swelling) following treatment.

Identifying people who are at a very high-risk of developing rheumatoid arthritis can also provide a better understanding of the changes in the body’s immune system that lead to rheumatoid arthritis. This could lead to the development of new treatments that target the very earliest phase of the disease.

Rheumatoid arthritis is an autoimmune condition that causes pain and inflammation in the joints. It affects around 400,000 people in the UK and is at present incurable. Many factors are known to contribute to an individual’s risk of developing rheumatoid arthritis. These are divided into two categories: inherited genetic factors (46 genetic risk factors have been identified that increase someone’s risk of developing rheumatoid arthritis) and so called “environmental” factors such as smoking.

The new computer-based technique of prediction modeling allows researchers to combine both genetic and environmental risk factors to estimate an individual’s lifetime risk of developing this disease.

According to the study’s lead researcher, Dr. Ian Scott, Department of Genetics & Molecular Medicine at King’s College London (United Kingdom), this new prediction modeling technique can also identify people at risk of developing rheumatoid arthritis at a younger age. “Within the general population, few individuals that have clinically significant increased risks are likely to be identified using this approach. But targeted screening of people already at an increased risk of rheumatoid arthritis, such as relatives of patients, could identify enough high-risk people to allow researchers to look at ways to prevent rheumatoid arthritis from developing.” This research is published in PLoS Genetics, September 19, 2013.

Individuals classed as being high risk, using information from the most important gene associated with rheumatoid arthritis (the HLA-DRB1 gene), are more likely to develop rheumatoid arthritis at a younger age. They could be monitored for early signs of the disease. Treating rheumatoid arthritis early, before significant joint damage has occurred, increases the likelihood that the individual will go into remission (no joint pain or swelling) following treatment.

Identifying people who are at a very high-risk of developing rheumatoid arthritis can also provide a better understanding of the changes in the body’s immune system that lead to rheumatoid arthritis. This in turn could lead to the development of new treatments that target the very earliest phase of the disease.

Dr. Scott added that as knowledge of the genetic and environmental risk factors that cause rheumatoid arthritis increases, it will improve the accuracy with which it is possible to predict an individual’s chance of developing this disease, and allow researchers to investigate new ways to stop it in its tracks before any symptoms develop.

Related Links:

Department of Genetics & Molecular Medicine at King’s College London






Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.